Compare Acadia Healthcare Company Inc (ACHC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Acadia Healthcare Company Inc vs Twist Bioscience Corp — how do they compare? Acadia Healthcare Company Inc trades at $31.18 (market cap $2.96B), while Twist Bioscience Corp trades at $123.13 (market cap $7.82B). The key difference: Twist Bioscience Corp is far larger — about 2.6× Acadia Healthcare Company Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Acadia Healthcare Company Inc nearer its low. Which is the better fit depends on your goals.
| ACHC | TWST | |
|---|---|---|
Market Cap | $2.96B | $7.82B |
Sector | Health | Health |
52-Week High | $35.61 | $124.88 |
52-Week Low | $11.68 | $24.16 |
Enterprise Value | $5.35B | $7.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.53, up 2.64% today, with a neutral technical signal despite bullish moving averages. The company shows strong revenue growth with Q2 2026 earnings beating estimates, but faces profitability challenges with negative net income margins. Analyst consensus remains positive with 68% buy ratings and a $36 price target, though ongoing legal investigations create headwinds.
The outlook balances operational strength against financial risks. Revenue growth and facility expansion support upside potential, but negative profitability and legal uncertainties warrant caution. The stock offers 14% upside to consensus target if execution improves, but investors should monitor earnings sustainability and legal developments closely.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Acadia Healthcare Company Inc
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
